{"filing":{"accession_number":"0001217234-26-000038","cik":"0001217234","ticker":"CDNA","company_name":"CareDx, Inc.","form":"8-K","filing_date":"2026-07-07","report_date":null,"primary_document":"cdna-20260630.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1217234/000121723426000038/cdna-20260630.htm"},"events":[{"id":16517,"run_id":14756,"accession_number":"0001217234-26-000038","anchor_item_number":"2.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"CareDx completed two material M\u0026A transactions: (1) sale of CareDx AB and lab products business to Eurobio Scientific for $171.7 million cash on June 30, 2026, and (2) acquisition of Naveris, Inc. for $161.8 million cash plus up to $100 million in contingent consideration on July 1, 2026. These transactions materially reshape CareDx's business portfolio by divesting its European lab products business while acquiring a high-growth specialty oncology diagnostics platform (NavDx) that expands the addressable market to $12+ billion.","company_name":"CareDx, Inc.","ticker":"CDNA","filing_date":"2026-07-07","form":"8-K","submitted_at":null,"items":[{"id":14641,"accession_number":"0001217234-26-000038","item_number":"2.01","item_title":"Completion of Acquisition or Disposition of Assets.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Item 2.01 discloses completion of two material M\u0026A transactions: (1) sale of CareDx AB and lab products business to Eurobio Scientific for $171.7 million cash on June 30, 2026, and (2) acquisition of Naveris, Inc. for $161.8 million cash plus up to $100 million in contingent consideration on July 1, 2026. Both transactions materially reshape CareDx's business portfolio—divesting its European lab products business while acquiring a high-growth specialty oncology diagnostics platform (NavDx) that expands the addressable market to $12+ billion. These are clearly material M\u0026A completions under Item 2.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T21:13:41.093435+00:00","company_name":"","ticker":null,"filing_date":""},{"id":14642,"accession_number":"0001217234-26-000038","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"CareDx disclosed the completion of two material M\u0026A transactions: (1) the sale of its Lab Products business to Eurobio Scientific for $171.2 million in cash (closed June 30, 2026), and (2) the acquisition of Naveris (closed July 1, 2026). These transactions materially reshape the company's business portfolio, divesting legacy lab products while acquiring a high-growth specialty oncology platform (NavDx) that generated $35 million in 2025 revenue and expands the addressable market to over $12 billion. Both closings represent completion of previously announced material acquisitions and dispositions.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T21:13:41.093435+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14641,"accession_number":"0001217234-26-000038","item_number":"2.01","item_title":"Completion of Acquisition or Disposition of Assets.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Item 2.01 discloses completion of two material M\u0026A transactions: (1) sale of CareDx AB and lab products business to Eurobio Scientific for $171.7 million cash on June 30, 2026, and (2) acquisition of Naveris, Inc. for $161.8 million cash plus up to $100 million in contingent consideration on July 1, 2026. Both transactions materially reshape CareDx's business portfolio—divesting its European lab products business while acquiring a high-growth specialty oncology diagnostics platform (NavDx) that expands the addressable market to $12+ billion. These are clearly material M\u0026A completions under Item 2.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T21:13:41.093435+00:00","company_name":"CareDx, Inc.","ticker":"CDNA","filing_date":"2026-07-07"},{"id":14642,"accession_number":"0001217234-26-000038","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"CareDx disclosed the completion of two material M\u0026A transactions: (1) the sale of its Lab Products business to Eurobio Scientific for $171.2 million in cash (closed June 30, 2026), and (2) the acquisition of Naveris (closed July 1, 2026). These transactions materially reshape the company's business portfolio, divesting legacy lab products while acquiring a high-growth specialty oncology platform (NavDx) that generated $35 million in 2025 revenue and expands the addressable market to over $12 billion. Both closings represent completion of previously announced material acquisitions and dispositions.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T21:13:41.093435+00:00","company_name":"CareDx, Inc.","ticker":"CDNA","filing_date":"2026-07-07"}]}